

EKF Diagnostics Holdings plc
("EKF" or the "Company")

**Share Buyback
& Completion of Share Buyback Programme**

EKF Diagnostics Holdings plc(AIM: EKF), theAIM-listed global diagnostics business,announces that it has purchased a total of 159,000 of its ordinary shares of 1p each in the capital of the Company ("**Ordinary Shares**") at a weighted average price of 25.6875 pence per share. The Ordinary Shares purchased will be held in treasury.

This transaction marks the successful conclusion of the share buyback programme announced on 21 May 2025 and the subsequent extension as set out in the announcement on 21 October 2025. Pursuant to the share buyback programme, a total of 17,130,678 ordinary shares were purchased at a weighted average cost of 26.14 pence per Ordinary Share.

Aggregated information

Date of purchase	30 January 2026
Number of Ordinary Shares purchased	159,000
Highest price paid per Ordinary Share	25.8000p
Lowest price paid per Ordinary Share	25.5000p
Volume weighted average price paid	25.6875p

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

Number of Ordinary Shares purchased	Transaction price (GBp)	Time of transaction	Trading venue
25,000	25.8000p	10:10:25	AIMX
45,000	25.8000p	11:44:21	AIMX
42,000	25.5000p	11:51:53	AIMX
47,000	25.6875p	15:37:38	AIMX

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 435,383,092 Ordinary Shares, of which 3,419,980 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 431,963,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

PDMR dealing

As part of the buyback and within the above aggregate purchase, EKF acquired 47,000 Ordinary Shares in total at a price of 25.6875 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("**Oryx**") and North Atlantic Smaller Companies Investment Trust PLC

International Securities Exchange (NYSE) and the relevant issuer's company's investment trust ("NASCIT"). EKF acquired 15,667 and 31,333 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.

Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 127,381,000 Ordinary Shares.

Additional disclosures relating to this PDMR dealing are detailed below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

*The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.*

EKF Diagnostics Holdings plc
Julian Baines, Executive Chair
Gavin Jones, Chief Executive Officer

www.ekfdiagnostics.com
via Walbrook PR

Tel: +44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Broker)
Phil Davies / Patrick Weaver

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Christopher Mills
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	EKF Diagnostics Holdings plc					
b)	LEI	213800DXTF3EAUUK1AR05					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each GB0031509804					
b)	Nature of the transaction	Disposal of Ordinary Shares					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>25.6875p</td><td>47,000</td></tr></table>		Price(s)	Volume(s)	25.6875p	47,000
Price(s)	Volume(s)						
25.6875p	47,000						
d)	Aggregated information - Aggregated volume - Price	n/a					
e)	Date of the transaction	30 January 2026					
f)	Place of the transaction	London Stock Exchange, AIMX					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFZGGZZMGGVZZ